YS VS DRRX Stock Comparison

Performance

YS
10/100

YS returned -94.73% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

DRRX
10/100

DRRX returned -58.52% in the last 12 months. Based on SPY's performance of -20.62%, its performance is below average giving it a score of 10 of 100.

Volatility

YS
23/100

YS has had a lower than average amount of volatility over the last 12 months giving it a score of 22 of 100.

DRRX
46/100

DRRX has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.

Analyst Price Targets

YS

"Analyst Price Targets" not found for YS

DRRX
58/100

3 analysts offer 12-month price targets for DRRX. Together, they have an average target of 0, the most optimistic target put DRRX at 0 within 12-months and the most pessimistic has DRRX at 0.

Sentiment

YS

"Sentiment" not found for YS

DRRX
71/100

DRRX had a bullish sentiment score of 71.07% across Twitter and StockTwits over the last 12 months. It had an average of 8.27 posts, 8.63 comments, and 19.71 likes per day.

Technicals

YS

"Technicals" not found for YS

DRRX
11/100

DRRX receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

YS

"Earnings" not found for YS

DRRX
10/100

DRRX has missed earnings 6 times in the last 20 quarters.

Profit

YS

"Profit" not found for YS

DRRX
13/100

Out of the last 20 quarters, DRRX has had 2 profitable quarters and has increased their profits year over year on 2 of them.

All score calculations are broken down here to help you make more informed investing decisions

YS Biopharma Co., Ltd. Ordinary Shares Summary

Nasdaq / YS

Healthcare

Biotechnology

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. It develops a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.

Durect Corp Summary

Nasdaq / DRRX

Healthcare

Drug Manufacturers - Specialty & Generic

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Power up your portfolio